Barry Paul

1.2k total citations
43 papers, 395 citations indexed

About

Barry Paul is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Barry Paul has authored 43 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 24 papers in Molecular Biology and 17 papers in Oncology. Recurrent topics in Barry Paul's work include Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (15 papers) and Peptidase Inhibition and Analysis (8 papers). Barry Paul is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (15 papers) and Peptidase Inhibition and Analysis (8 papers). Barry Paul collaborates with scholars based in United States, Jordan and United Kingdom. Barry Paul's co-authors include Yubin Kang, Susan K. Gilmour, Cheryl A. Hobbs, Saad Z. Usmani, Daniel Feinberg, Cesar Rodriguez, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees and Enrique M. Ocio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Barry Paul

38 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Barry Paul United States 12 254 165 145 47 39 43 395
Bettina Wingelhofer Austria 9 205 0.8× 74 0.4× 123 0.8× 93 2.0× 54 1.4× 12 377
Yu Jia United States 8 259 1.0× 76 0.5× 44 0.3× 69 1.5× 36 0.9× 14 373
Craig T. Wallington‐Beddoe Australia 14 501 2.0× 259 1.6× 143 1.0× 74 1.6× 79 2.0× 32 658
Christelle Dubey Switzerland 5 313 1.2× 31 0.2× 127 0.9× 48 1.0× 53 1.4× 10 428
Candice McCoy United States 11 286 1.1× 31 0.2× 233 1.6× 106 2.3× 52 1.3× 27 501
Sreedhar Venkannagari United States 6 341 1.3× 115 0.7× 97 0.7× 25 0.5× 36 0.9× 8 415
Stuart Murray United States 6 290 1.1× 81 0.5× 43 0.3× 60 1.3× 82 2.1× 8 392
Iryna Kolosenko Sweden 11 237 0.9× 43 0.3× 116 0.8× 68 1.4× 91 2.3× 19 383
Johannes Schmoellerl Austria 6 226 0.9× 63 0.4× 96 0.7× 38 0.8× 83 2.1× 11 354
Elizabeth Moskatel United States 3 318 1.3× 22 0.1× 96 0.7× 67 1.4× 44 1.1× 4 389

Countries citing papers authored by Barry Paul

Since Specialization
Citations

This map shows the geographic impact of Barry Paul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barry Paul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barry Paul more than expected).

Fields of papers citing papers by Barry Paul

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barry Paul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barry Paul. The network helps show where Barry Paul may publish in the future.

Co-authorship network of co-authors of Barry Paul

This figure shows the co-authorship network connecting the top 25 collaborators of Barry Paul. A scholar is included among the top collaborators of Barry Paul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barry Paul. Barry Paul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bhutani, Manisha, Myra Robinson, David Foureau, et al.. (2024). MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma. Blood Advances. 9(3). 507–519. 3 indexed citations
3.
Richard, Shambavi, Alexander M. Lesokhin, Barry Paul, et al.. (2024). Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nature Cancer. 5(10). 1459–1464. 8 indexed citations
4.
Paul, Barry, Hamza Hashmi, Nausheen Ahmed, et al.. (2024). Patient Outcomes Following First and Second Exposure to BCMA-Directed Therapies Including CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma. Transplantation and Cellular Therapy. 30(2). S394–S395. 1 indexed citations
5.
Bhutani, Manisha, David Foureau, Myra Robinson, et al.. (2023). A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse. Clinical Lymphoma Myeloma & Leukemia. 23(7). 535–544.e1. 2 indexed citations
6.
Mansour, Razan, Hamza Hashmi, Aimaz Afrough, et al.. (2023). Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics. Blood. 142(Supplement 1). 1985–1985.
7.
Mahmoudjafari, Zahra, Wei Cui, Shebli Atrash, et al.. (2023). Adverse Hematological and Non-Hematological Events in Patients With Relapsed/Refractory Multiple Myeloma That Are Responsive to Daratumumab, Pomalidomide and Dexamethasone. Journal of Hematology. 12(1). 1–6. 1 indexed citations
8.
Atrash, Shebli, Myra Robinson, Barry Paul, et al.. (2023). Bone marrow Ki‐67 index is of prognostic value in newly diagnosed multiple myeloma. European Journal Of Haematology. 111(3). 373–381. 5 indexed citations
9.
10.
Paul, Barry, Cesar Rodriguez, & Saad Z. Usmani. (2022). BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs. 82(6). 613–631. 20 indexed citations
11.
Sha, Yonggang, Jian Wu, Barry Paul, et al.. (2022). PPAR agonists attenuate lenalidomide's anti-myeloma activity in vitro and in vivo. Cancer Letters. 545. 215832–215832. 7 indexed citations
12.
Foureau, David, Barry Paul, Fei Guo, et al.. (2022). Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23(1). e41–e50. 8 indexed citations
13.
Patel, Jai N., Myra Robinson, Megan H. Jagosky, et al.. (2020). Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug–Based Regimens. Clinical Lymphoma Myeloma & Leukemia. 21(3). 188–198.e2. 5 indexed citations
14.
Moore, Donald C., Justin Arnall, Barry Paul, et al.. (2020). Evaluation of Montelukast for the Prevention of Infusion-related Reactions With Daratumumab. Clinical Lymphoma Myeloma & Leukemia. 20(10). e777–e781. 10 indexed citations
15.
Bhutani, Manisha, Jiaxian He, Shebli Atrash, et al.. (2020). Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma. Blood. 136(Supplement 1). 38–39. 6 indexed citations
16.
Paul, Barry, et al.. (2019). Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma. Journal of Cancer Metastasis and Treatment. 2019. 43 indexed citations
17.
Paul, Barry, et al.. (2018). The challenges of checkpoint inhibition in the treatment of multiple myeloma. Cellular Immunology. 334. 87–98. 16 indexed citations
18.
Ivanova, Anastasia, et al.. (2015). Nine-year change in statistical design, profile, and success rates of Phase II oncology trials. Journal of Biopharmaceutical Statistics. 26(1). 141–149. 15 indexed citations
19.
Hobbs, Cheryl A., et al.. (2006). Tip60 Protein Isoforms and Altered Function in Skin and Tumors that Overexpress Ornithine Decarboxylase. Cancer Research. 66(16). 8116–8122. 22 indexed citations
20.
Hobbs, Cheryl A., Barry Paul, & Susan K. Gilmour. (2003). Elevated levels of polyamines alter chromatin in murine skin and tumors without global changes in nucleosome acetylation. Experimental Cell Research. 290(2). 427–436. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bettina Wingelhofer Breakdown of academic impact, for papers by Yu Jia Breakdown of academic impact, for papers by Craig T. Wallington‐Beddoe Breakdown of academic impact, for papers by Christelle Dubey Breakdown of academic impact, for papers by Candice McCoy Breakdown of academic impact, for papers by Sreedhar Venkannagari Breakdown of academic impact, for papers by Stuart Murray Breakdown of academic impact, for papers by Iryna Kolosenko Breakdown of academic impact, for papers by Johannes Schmoellerl Breakdown of academic impact, for papers by Elizabeth Moskatel
Rankless by CCL
2026